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Abstract
Introduction: The American Heart Association (AHA)/American College of
Cardiology (ACC) guidelines for the classification of heart failure (HF) are
descriptive but lack precise and objective measures which would assist in
categorising such patients. Our aim was two fold, firstly to demonstrate
quantitatively the progression of HF through each stage using a meta-analysis of
existing left ventricular (LV) pressure-volume (PV) loop data and secondly use the
LV PV loop data to create stage specific HF models.
Methods and Results: A literature search yielded 31 papers with PV data,
representing over 200 patients in different stages of HF. The raw pressure and
volume data were extracted from the papers using a digitising software package
and the means were calculated. The data demonstrated that, as HF progressed,
stroke volume (SV), ejection fraction (EF%) decreased while LV volumes
increased. A 2-element lumped parameter model was employed to model the mean
loops and the error was calculated between the loops, demonstrating close fit
between the loops. The only parameter that was consistently and statistically
different across all the stages was the elastance (Emax).
Conclusions: For the first time, the authors have created a visual and quantitative
representation of the AHA/ACC stages of LVSD-HF, from normal to end-stage. The
study demonstrates that robust, load-independent and reproducible parameters,
such as elastance, can be used to categorise and model HF, complementing the
existing classification. The modelled PV loops establish previously unknown
physiological parameters for each AHA/ACC stage of LVSD-HF, such as LV
elastance and highlight that it this parameter alone, in lumped parameter models,
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that determines the severity of HF. Such information will enable cardiovascular
modellers with an interest in HF, to create more accurate models of the heart as it
fails.
Introduction
To model LV performance, quantitative data, such as pressure and volume, is vital
to ensure that any model is an accurate representation of reality. As such, a
computational model of the LV cannot be built on single parameters alone such as
left ventricular end-diastolic volume (LVEDV), subjective symptoms such as
dyspnoea, nor surrogate markers such as natriuretic peptides (NP’s) but direct
measures of the system being modelled, both anatomical e.g. volume and
physiological e.g. pressure.
Previous attempts to model the HF, and the effect of potential therapies, have
applied hypothetical haemodynamic states according to symptomatic New York
Heart Association (NYHA) class rather than actual patient data, from individuals
or populations. The NYHA class, whilst useful clinically, correlates poorly with
even non-invasive measures of LV performance [1, 2]. Current computational
models of HF, regardless of complexity, choose arbitrary parameters for the LV
such as reducing contractility by 50% or boundary conditions such as resistance
and compliance from healthy populations. Clearly, it is not just the ‘‘pump’’ that
fails during HF, but also the vasculature, among other systems, and each may
augment the decline of the other. The authors aimed to provide specific LV
performance and systemic vascular data on a population basis, to track the
progression from a healthy to a failing heart. In doing so, for the first time, give
the modelling community access to disease and severity specific variables derived
from real patients, to enable the creation of more accurate models.
In 2001, the joint American Heart Association (AHA)/American College of
Cardiology (ACC) guidelines categorised for the first time HF and its progression
in terms of pathophysiology (see table 1). This was intended to ‘‘complement’’ the
pre-existing NYHA functional classification and the development of HF, from risk
e.g. hypertension (Stage A) to end-stage e.g. requiring transplant (Stage D) [3].
Whilst the guidelines have subsequently been updated, the classification remains
qualitative and is often misunderstood [4, 5]. The addition of quantitative
measures for each stage could be used to more accurately chart the
pathophysiology and enable the development HF models based on objective
parameters. Such measures may also improve risk stratification and predict
response to clinical interventions. To date, attempts to categorize patients into
individual AHA/ACC stages have focussed on indirect measures, such as NP’s,
which nonetheless improve prognostication [6].
The authors wished to define quantitatively each AHA/ACC stage of HF and so
for the first time define the risk and the onset and progression of left ventricular
Closing the Loop
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systolic dysfunction heart failure (LVSD-HF) according to objective changes in
left ventricular physical properties represented by the left ventricular pressure-
volume loops. The choice of the pressure-volume (PV) loop is based on its direct
description of the performance of the LV in real-time and for reasons mentioned
above, quantifying LVSD-HF by other parameters such as LV volume or
symptoms is insufficient for modelling purposes.
For this study, we concentrated on the chronic LVSD-HF population based on
both pragmatic approach, and a more therapeutic consideration since only
patients with LVSD-HF have interventions that are associated with significant
impact on morbidity and mortality. There have been many studies looking at LV
PV loops in patients with heart disease, but this is the first time they have all been
collated, compared and modelling parameters derived. For comparision and
completeness, a healthy normal group (stage O) was created also, not contained in
the AHA/ACC guidelines,
Methods
PV loops
The methodology for PV loop acquisition has been described in detail previously
[7, 8]. Briefly, a specialised catheter is inserted via the femoral artery to the apex of
the LV cavity under fluoroscopy (see figure 1). Real-time measurement of
pressure is performed using a micro manometer on the catheter, and of volume,
using the conductance method. The conductance method refers to the usage of
linearly placed electrodes on the catheter, each measuring segmental volumes, this
utilises excitation and recording electrodes, the former generate an electric field,
and the latter measure a change in voltage proportional to resistance. A
mathematical formula is then used to calculate the total volume of the LV cavity,
which takes into account the distance between the electrodes and the blood pool
resistivity.
An online literature search of Pubmed, Web of Knowledge, Medline and
Google, using the search term ‘‘pressure volume loop’’ was conducted and the
references were studied to check that they met criteria to be included in the final
analysis (see figure 2).
Table 1. The American Heart Association/American College of Cardiology Heart Failure classification From Jessup et al. (2009) [4].
Stage Description Examples
A Risk of heart failure but without structural heart disease e.g. Hypertension
B Structural heart disease without signs or symptoms e.g. Previous myocardial infarction
C Structural heart disease with prior or current symptoms e.g. Patients requiring routine drugs
D Refractory heart failure requiring specialist intervention e.g. Heart transplant
doi:10.1371/journal.pone.0114153.t001
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Inclusion criteria
Studies with complete LV PV loops in adult humans in English.
(and) Studies representing any AHA/ACC stage including healthy normal
subjects.
(and) HF, if present, due to chronic LVSD-HF only.
Exclusion criteria
Diastolic HF or HFPEF.
HF secondary to an uncommon cause such as Chagas’ disease.
An unclear past medical, symptom or drug history, meaning HF stage was
vague.
No pictorial representation of an entire loop, such as a diastolic limb only.
Acquisition during experimental treatment only without a baseline measure
Of the papers identified, 97 were potentially useable, but only 31 met the
inclusion, and not the exclusion, criteria and so were included in the final analysis,
accounting for 203 patients [9–38].
Engauge digitizing software (http://digitizer.sourceforge.net/) was then used to
upload the graphical PV loop images from the original studies and convert them
into numerical data, as seen in figure 3 [39]. This freeware allows users to upload
a graphical image, such as a PV loop, in variety of formats such as a Joint
Photographic Experts Group (JPEG) file, and convert a pictorial image into
numerical data. After loading the file, the parameters of the axes (red crosshairs)
were chosen, with X corresponding to 80–280 ml and Y 0–150 mmHg
respectively. The PV loop is then digitised automatically (blue crosshairs), turning
the PV loop picture into a series of individual pressure and volume data points, 10
points per limb of the curve, giving a total of 40 data points for each PV loop. The
LV PV loops from each LVSD-HF stage were converted into digital values and
these were then tabulated and the mean for each calculated.
Figure 1. Combined pressure-volume catheter (in black) positioned in the left ventricular cavity. The
micromanometer can be seen at level 3 and the 6 electrodes (white markers) mapping the volume of each of
the 5 segments (reproduced with permission, from Steendijk et al. (2004)).
doi:10.1371/journal.pone.0114153.g001
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Figure 2. Flow diagram demonstrating inclusion and exclusion criteria for left ventricular pressure-volume loop studies. HFPEF5 heart failure with
preserved ejection fraction, LV 5 left ventricle, LVSD 5 left ventricular systolic dysfunction, PV 5 pressure volume,
doi:10.1371/journal.pone.0114153.g002
Figure 3. Screenshot from Engauge - on the left, the pressure volume loop is seen, with red cross hairs denoting X and Y axes, and blue
crosshairs which correspond with the numerical values of pressure and volume seen in the table on the right. LV 5 left ventricle.
doi:10.1371/journal.pone.0114153.g003
Closing the Loop
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Modelling the PV loops
Various computational models exist in the engineering literature of the
cardiovascular system, from simple lumped parameter to more complex 3
dimensional models. The purpose of the lumped parameter models is to describe
the changes in pressure, volume and flow that occur over the cardiac cycle as a
function of cardiac performance and systemic afterload. This paper presents the
numerical values of the four parameters in the simplest possible representation of
the heart and systemic circulation; LV elastance (maximum and minimum), total
peripheral resistance and systemic vascular compliance, the components of which
are described below. The progression of LVSD-HF is thus expressed in terms of
the evolution of these four parameters. Furthermore it is suggested that the values
of the components that represent the systemic afterload might be used to
determine appropriate boundary conditions for the modeller who is interested in
using such representations for complex 3D models of the left ventricle, which still
rely on a specific afterload for the LV to ‘‘push’’ against.
A lumped parameter model represents complex systems such as the
cardiovascular system as a hydro-electrical analogue. In particular, the Windkessel
model (meaning ‘‘air chamber’’ in German) contains a two element afterload, a
capacitor representing the elastic property of the large arteries which determines
systemic vascular compliance (C) and a resistor representing the frictional loss in
the smaller vessels e.g. arterioles which determine the total peripheral resistance
(R). The LV is represented by a variable elastance (E) model, where by the LV
pressure is a function of the LV elastance and the change in LV volume from its
resting state, in this model E is represented by 2 values, Emax being representative
of peak systolic LV contractility and Emin being representative of end diastolic LV
stiffness. Using software such as OpenCell, (http://www.cellml.org/tools/opencell)
such models can be run and the input variables of E, R and C manipulated, for
example, to model hypertension one could reduce the compliance and increase
the resistance of the vasculature, whilst leaving the value of E unaltered. The
resulting outputs of LV pressure and volume can be exported to a database,
extracted from one cardiac cycle and then converted into a PV loop.
For this study, a lumped parameter model with a variable elastance LV and 2
element (R and C) Windkessel afterload was chosen to model the LV in LVSD-HF
[40]. It was chosen due to its elegance in representing the cardiovascular system,
simplicity in manipulation, low computational demands and experience within
the research group. This was downloaded from the CellML (http://www.cellml.
org/) model repository, which is a free to access store of computer based
mathematical models, and run using OpenCell, an open source platform for
working with CellML models, see figure 4 [41]. In this model the left atrium (ELA)
and left ventricle (ELV) are represented by variable capacitors to model the
pumping action of the left side of the heart, the mitral (mi) and aortic (ao) valves
are represented by diodes to model unidirectional flow, the total peripheral
resistance by a resistor, systemic vascular compliance by a capacitor and blood
vessels by wire allowing for flow of electrons, representing the flow of blood.
Closing the Loop
PLOS ONE | DOI:10.1371/journal.pone.0114153 December 5, 2014 6 / 19
To model the mean AHA/ACC PV loops, the Matlab (Mathworks, MA, USA)
optimisation toolbox was used to find the combination of parameters that best
fitted the data. This toolbox enabled running the lumped parameter model as an
iterative process, whilst varying each variable (Emax, Emin, R and C) until the
best-fit model for the patient derived mean LV PV loop for each stage was created.
The resulting model PV loop data was exported to a spreadsheet and compared
against the mean loops (see below).
Statistics
Statistical analysis was carried out using Microsoft Excel 2010 software (Microsoft,
CA, USA). Parametric data is given as mean (¡ SD). Comparison of data between
LVSD-HF stages using an unpaired 2 tailed Students t-test and p values of ,0.05
were considered significant.
Results
Mean PV loops
The majority of the patients making up each category are males in their late fifties
(see table 2). Some AHA/ACC LVSD-HF stage groups have more patients than
others and group A is dominated by ischaemic heart disease (IHD), rather than
other risk factors such as obesity or diabetes. However, there is a balanced
distribution of LVSD-HF aetiologies in both groups C and D, with both ischaemic
Figure 4. Schematic diagram of Zero-D model of the cardiovascular system, with the heart comprised
of variable capacitors representing elastance of the LA (ELA) and LV (ELV) and the aortic (ao) and mitral
valves (mi) by diodes. The systemic loop is comprised of a systemic arterial compliance represented by a
capacitor (CV) and total peripheral resistance by a resistor (RV).
doi:10.1371/journal.pone.0114153.g004
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and idiopathic dilated cardiomyopathy (DCM) accounting for approximately
50% each.
Figure 5 demonstrates all of the individual patient loops together with the mean
loops from each stage. As one can see from figure 6, there is a conformational
difference not only between all stages O-D but also between those asymptomatic
or at risk groups A-B and those in symptomatic LVSD-HF groups C-D. Table 3
shows that as one progresses from normal LV function to symptomatic LVSD-HF
due to left ventricular systolic dysfunction: the LV volumes and diastolic pressures
rise, and the stroke volume (SV), ejection fraction (EF%) and systolic pressure
fall. Furthermore, the maximal elastance of the LV falls, as the disease progresses.
For clarity, we have just shown the raw and mean loops from one stage, AHA/
ACC D (figure 7). It is evident that even within AHA/ACC stages there is
individual variation, both in terms of LV pressure and volume. Figure 8
demonstrates the standard error for each of the PV points derived from patients in
this stage, reflecting this large spread. Table 4 demonstrates, that there is no
statistically significance differences between stages O and A or B, but together they
are significantly different from stages C and D in all variables, other than other
than minimal elastance. There are no significant differences between stages C and
D.
Modelled PV loops
For the modelled PV loops (see figure 9) there is a more accurate fit for the loops
representing the earlier AHA/ACC LVSD-HF stages, which reduces as the LV
contraction deteriorates and the stage progresses. Table 5, shows how the
modelled LV elastance falls from a normal LV to end-stage HF due to LVSD; the
volume of the LV increases but yet the resistance and compliance of the systemic
vasculature remain unchanged.
Table 6 demonstrates, that there is no statistically significance difference
between model parameters between stages O and A or B, but they are significantly
different from stages C and D in Emax only. There were no significant differences
between stages C and D.
Using Matlab (Mathworks, MA, USA), we compared the area error for the
modelled loops to the mean, to give a measurement of accuracy (see table 5 and
figure 10). This method compared the area occupied by the mean PV loop
derived from the patient (white) data against the mean PV loop created from the
lumped parameter model (black) to give an overlapping area (grey). Because the
modelled loops are based on mean data, modelling the size, rather than the shape
of the PV loops is important. Thus we compared the overlapping area of the mean
and modelled loops as a measure of closeness of fit against that area which did not
overlap. The area, which was not overlapping e.g. the error, was calculated as a
percentage of the total, giving an overall mean error for all stages of less than 10%.
Comparing the mean and modelled PV loop data statistically; there were no
significant differences at any stage (not shown).
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Table 2. Demographic information on the patients comprising the left ventricular pressure volume loops.
AHA/ACC HF Stage O A B C D
Demographics Number of patients Total population 20 144 88 62 129
Patients with loops 2 65 6 42 92
Gender % male 75 65 77 88 84
Age mean 29 56 59 60 58
Aetiology HTN % 7
IHD % 93
MI % 100
Ischaemic DCM % 50 54
Idiopathic DCM % 50 46
HTN – hypertension, IHD – ischaemic heart disease, MI – myocardial infarction, DCM – dilated cardiomyopathy.
doi:10.1371/journal.pone.0114153.t002
Figure 5. Graph showing the progression of HF by individual PV (thin, pale lines) and averaged (thick, dark lines) loops for all the American Heart
Association (AHA)/American College of Cardiology (ACC) heart failure (HF) stages including stage O (blue), A (red), B (green), C (yellow) and D
(purple).
doi:10.1371/journal.pone.0114153.g005
Closing the Loop
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Discussion
This is the first meta-analysis of all of the existing literature on PV loops in LVSD-
HF, stratified by AHA/ACC stage. This study demonstrated that the pressure-
volume data in the literature supports the existing theoretical ACC/AHA
physiological paradigm for LVSD-HF, whereby as the left ventricle fails, it dilates.
Thus, the contractile force is impaired and the volume it ejects with each beat is
reduced. This study showed quantitatively the changes between each AHA/ACC
stage. As the AHA/ACC stages are descriptive and qualitative, particularly stages C
and D, it is remarkable how the stages could be delineated quantitatively in this
study. Indeed, it demonstrates the strength of the EF, although typically used in
echocardiography or cardiac magnetic resonance, as it is the only variable in the
patient data, that is statistically and significantly different across all the stages,
other than between O and A.
For the first time, a LPM has been used to model all the existing PV loop data
across the entire spectrum of heart disease, from healthy normal individuals to
patients with end-stage LVSD-HF. The model, whilst simple, performed well, with
Figure 6. Graph showing the progression of HF by mean PV loops for all the American Heart
Association (AHA)/American College of Cardiology (ACC) heart failure (HF) stages including stage O
(solid black diamonds), A (black crosses), B (white circles), C (solid black squares) and D (white
triangles).
doi:10.1371/journal.pone.0114153.g006
Table 3. Mean left ventricle parameters for each stage of heart failure (with standard deviation in brackets).
AHA/ACC HF Stage O A B C D
LV parameters LVESV (ml) 48 (21) 66 (52) 93 (48) 166 (61) 210 (96)
LVEDV (ml) 138 (7) 154 (33) 161 (49) 237 (62) 273 (98)
SV (ml) 89 (14) 88 (29) 68 (23) 71 (21) 63 (30)
EF (%) 0.65 (0.01) 0.57 (0.10) 0.45 (0.16) 0.32 (0.10) 0.25 (0.10)
Elastance (mmHg/ml) 2.23 (0.26) 2.27 (0.29) 1.32 (0.73) 0.63 (0.36) 0.55 (0.23)
Stiffness (mmHg/ml) 0.17 (0.01) 0.09 (0.06) 0.10 (0.03) 0.06 (0.04) 0.08 (0.04)
LV 5 left ventricle, LVESV 5 left ventricular end systolic volume, LVEDV 5 left ventricular end diastolic volume, EF 5 ejection fraction.
doi:10.1371/journal.pone.0114153.t003
Closing the Loop
PLOS ONE | DOI:10.1371/journal.pone.0114153 December 5, 2014 10 / 19
a mean error of less than 10% and gives insight into how the heart, and the
systemic vasculature fail.
The lumped parameter model is true in physiological sense. Predictably, the
pump function of the left ventricle deteriorates as LVSD-HF progresses, the left
ventricular chamber dilates, the afterload and plasma volume increase, which will
affect both R and C. The pressure-volume loops showed each stage as expected,
thus: Stage O is indeed healthy, with normal left ventricular parameters that we
would expect from a disease-free population. Patients in Stage A, the vast majority
of whom have IHD, the systolic pressure rises reflecting increased afterload and
the EF% and SV fall. However, all these parameters are still within normal limits.
Following an ischaemic insult to the myocardium in Stage B, there is a rise in
LVEDP reflecting increased stiffness, a fall in systolic pressure due to impaired
Figure 7. Graph showing mean pressure volume loop for American Heart Association (AHA)/American
College of Cardiology (ACC) heart failure (HF) stage D (white triangles) and the spread of the raw loops
sourced from the literature (grey lines).
doi:10.1371/journal.pone.0114153.g007
Figure 8. Graph showing mean pressure volume loop for each American Heart Association (AHA)/
American College of Cardiology (ACC) heart failure (HF) stage (shown as white triangles) and
standard error (shown black lines).
doi:10.1371/journal.pone.0114153.g008
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contractile force and corresponding reduction in both the ejection fraction and
the stroke volume. What is somewhat surprising is that whilst there is an increase
in volume from stage C to D, both the systolic and diastolic pressures rise. This is
not necessarily surprising as the process is not a simple mechanical process but it
reflects the contribution of the compensatory mechanisms driven by the
sympathetic drive and by the endocrine responses driven by the rennin-
angiotensin-aldosterone system as well as the sympathetic system.
The patients in stages A-B are asymptomatic from the LVSD-HF viewpoint, this
is despite an increase of R and C, and decrease in LV Emax, by 60% (relative to
Stage O). However, the remaining contractile force is sufficient to meet the
demands of the body. The difference between the asymptomatic patients with
structural heart disease (Stage B) and those with symptoms of (Stage C) is the
reduction in LV Emax by a further 50%. The difference between symptomatic and
Table 4. Statistical comparison of parameters from the patient data for each American Heart Association/American College of Cardiology heart failure stage,
using 2-tailed Student’s T-Test.
AHA/ACC HF
Stage Parameter Unit O A B C D
O LVEDV (ml) p50.31 p50.27 p,0.05 p,0.05
LVESV (ml) p50.22 p50.13 p,0.01 p,0.05
SV (ml) p50.49 p50.13 p50.11 p,0.001
EF (%) p50.19 p,0.05 p,0.001 p,0.001
Emax (mmHg/ml) p50.48 p50.05 p,0.001 p,0.001
Emin (mmHg/ml) p50.29 p50.19 p50.08 p50.39
A LVEDV (ml) p50.37 p,0.001 p,0.001
LVESV (ml) p50.05 p,0.001 p,0.001
SV (ml) p,0.05 p,0.01 p,0.001
EF (%) p,0.01 p,0.001 p,0.001
Emax (mmHg/ml) p,0.05 p,0.001 p,0.001
Emin (mmHg/ml) p50.47 p,0.001 p50.21
B LVEDV (ml) p,0.01 p,0.01
LVESV (ml) p,0.01 p,0.001
SV (ml) p50.39 p,0.001
EF (%) p,0.01 p,0.001
Emax (mmHg/ml) p,0.01 p,0.001
Emin (mmHg/ml) p,0.001 p50.29
C LVEDV (ml) p50.09
LVESV (ml) p50.08
SV (ml) p50.40
EF (%) p,0.05
Emax (mmHg/ml) p50.38
Emin (mmHg/ml) p50.18
AHA5 American Heart Association, ACC5 American College of Cardiology EF5 ejection fraction, LV5 left ventricle, LVESV5 left ventricular end systolic
volume, LVEDV 5 left ventricular end diastolic volume, SV 5 stroke volume.
doi:10.1371/journal.pone.0114153.t004
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refractory LVSD-HF is a further modest (13%) reduction in Emax (which
translates into an absolute fall of 75% compared to Stage O). This is an important
observation that illustrates the delicate tipping point between physiological
compensation and decompensation. Indeed, as seen statistically, stage C and D
were not significantly different from one another, but they were on almost every
single variable compared to stages O-B. This information, whilst logical and
perhaps inferred, was previously unknown. Also, there was no significant
difference between any of the groups in Emin, representing LV end-diastolic
stiffness, as one might expect, as this was a study investigating LVSD-HF, not
HFPEF, although diastolic dysfunction can co-exist with systolic.
Importantly, the creation of the lumped parameter model variables for the
various LVSD-HF stages (see table 4), will satisfy both the academic and clinical
communities. From simple lumped parameter to 3D models of the LV, all use pre-
defined boundary conditions, such as elastance, resistance and capacitance,
regardless of their complexity. From a clinical perspective, a model of the failing
heart, should utilise as much patient derived data as possible, not simply use
arbitrary measures. From a modelling perspective, a model must be based on
robust, repeatable and high fidelity measures of the system one seeks to represent,
not symptoms or biomarkers. For the first time in LVSD-HF, this novel work
enables both parties to use data that is academically rigorous, clinically
meaningful and enable the creation of patient and disease specific models.
Depending on the stage of the LVDS-HF, the modellers can choose the variables
to fit their theoretical cohort.
Previously, it was felt that the LV afterload, comprising total peripheral
resistance and systemic vascular compliance had an important role in modelling
the LV performance accurately. However, this body of work, comprising the
largest cohort of LVSD-HF models based on real patients to date, demonstrates
there is no significant different in compliance or resistance between even healthy
normals and end-stage. This is important as it demonstrates, that in LVSD-HF
and in this this model at least, the most important factor is Emax or peak
Figure 9. Graph showing the progression of heart failure by mean pressure volume loop for all
American Heart Association (AHA)/American College of Cardiology (ACC) heart failure stages from
O-D (various markers) along with the modelled loops (solid black lines).
doi:10.1371/journal.pone.0114153.g009
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contractility of the LV. Of course, in reality, it is well known that increased
afterload on the heart, due to diseases like hypertension, leads to increase LV wall
shear stress, left ventricular hypertrophy and if untreated LVSD and eventually
LVSD-HF. Afterload and compliance will also be influenced by other disease
processes and medications, which were impossible to control for and very few of
this patient cohort, particularly in stage A had hypertension. Our findings
however, further strengthen the importance of using load-independent, repeatable
and robust measures of LV performance such as elastance when modelling LVSD-
HF.
There is wide distribution of the PV loops within each stage, as demonstrated in
Stage D by figure 6 (other stages are similar, but for brevity they were not shown),
which means that there is difficulty stratifying the disease condition based on
current measures of LV function, such as LVEDV or SV. The mean loops from
stages B-C would also fit within the data range of stage D and the AHA/ACC
classification. This probably due to the lack of standardisation of LV volume
against body surface area e.g ml/m2 as undoubtedly in a cohort of over 200
patients, there will be large variations in patient size and anatomy. Hence, there is
overlap amongst the disease stages and accounts for the non-significance
difference in LV volume between the 5 stages. This further highlights the
importance of objective differentiation of patient LVSD-HF stages, when creating
models, rather than being based on the patient’s subjective assessment (although
the latter is clinically important) and objective echocardiographic measurements
used in current clinical practice.
Future work
It would be interesting to compare the PV loops of patients with HF of different
aetiologies, such as ischaemic versus idiopathic DCM, and to model the effects of
various therapies on the different parameters, such as cardiac resynchronisation
therapy (CRT). Furthermore, comparing those PV loops of patients with different
isolated risk factors for HF, such as obesity or essential hypertension or with
differing structural heart diseases such as asymptomatic aortic stenosis or left
ventricular hypertrophy to see how they progress from symptomless risk to
symptomatic HF would also be of interest. Unfortunately, such data are not
Table 5. Lumped parameter model variables and calculated error for each stage.
Parameter Unit AHA/ACC HF Stage
O A B C D
Emax (mmHg/ml) 2.50 2.20 1.14 0.55 0.52
Emin (mmHg/ml) 0.08 0.06 0.15 0.04 0.06
LV Volume (ml) 468 522 771 579 726
Resistance (mmHgNs/ml) 1.15 1.51 1.50 1.65 1.58
Compliance (ml/mmHg) 3.19 2.90 5.34 3.87 4.33
Percentage error (%) 7.5 3.0 7.5 15.0 10.6
doi:10.1371/journal.pone.0114153.t005
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currently available. More PV loops are needed to inform stages O and B, as the
mean loops and therefore the models, are based on a small number of cases.
However, it is unlikely that ethical approval for invasive PV loop analysis would
be granted for healthy subjects.
Drawbacks
Most of the information given about patients was not specific to the loop and so
we were unable to control for age, body mass, sex, medications and other relevant
co-morbidities (both cardiac, such as mitral regurgitation and non-cardiac, such
as renal failure), which could have an impact on the loop shape, size and position
[42]. Some curves were averaged already from a patient population (hence the
number of patients represented is greater than the number of loops) and what
may have been AHA D in previous decades, may be considered AHA C today. We
could not control for any differences in methodology across the papers. Most of
the PV loops are from middle-aged, probably white, male patients, reflecting the
fact the women are under-represented in HF clinical trials. We should not assume
women, ethnic minorities, or patients with conditions not represented e.g.
obesity, will be the same. As can be seen from figure 6, averaging the means that a
lot of the raw data is lost and the curves smoothed accordingly, thus a real patient
Table 6. Statistical comparison of the lumped parameter variables for each American Heart Association/American College of Cardiology heart failure stage
model, using 2-tailed Student’s T-test.
AHA/ACC HF
Stage Parameter Unit O A B C D
O Emax (mmhg/ml) p50.76 p50.81 p,0.001 p,0.001
Emin (mmhg/ml) p50.71 p50.65 p50.98 p50.77
LV Volume (ml) p50.76 p50.81 p50.17 p,0.001
Resistance (mmhgNs/ml) p50.06 p50.25 p50.48 p50.37
Capacitance (ml/mmhg) p50.67 p50.93 p50.71 p50.80
A Emax (mmhg/ml) p50.63 p,0.001 p,0.001
Emin (mmhg/ml) p50.06 p,0.05 p,0.001
LV Volume (ml) p50.27 p,0.05 p50.53
Resistance (mmhgNs/ml) p50.36 p50.21 p50.08
Capacitance (ml/mmhg) p50.41 p50.06 p50.07
B Emax (mmhg/ml) p,0.01 p,0.001
Emin (mmhg/ml) p50.16 p,0.001
LV Volume (ml) p50.88 p50.35
Resistance (mmhgNs/ml) p50.88 p50.35
Capacitance (ml/mmhg) p50.63 p50.35
C Emax (mmhg/ml) p50.43
Emin (mmhg/ml) p50.25
LV Volume (ml) p50.25
Resistance (mmhgNs/ml) p,0.05
Capacitance (ml/mmhg) p50.9
doi:10.1371/journal.pone.0114153.t006
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in stage D will not necessarily meet the mean values, but may fall within the range
of values given. Digitizing the PV loops was employed to allow access to the data
underlying each loop. Due to the duration of time that has passed since the
original publication of many of the papers, only a small number of authors were
contactable.
Conclusions
For the first time, the authors have created a visual and quantitative
representation of the AHA/ACC stages of LVSD-HF, from normal to end-stage.
The study demonstrates that robust, load-independent and reproducible
parameters, such as elastance, can be used to categorise and model HF,
complementing the existing classification. The modelled PV loops establish
previously unknown physiological parameters for each AHA/ACC stage of LVSD-
HF, such as LV elastance and highlight that it this parameter alone, in lumped
parameter models, that determines the severity of HF. This is the largest collection
of LV PV loop data, which has been used to create stage specific HF models, and
as such, will enable cardiovascular modellers to create more accurate models of
the heart as it fails and should be used as a reference for future work in this field.
Supporting Information
Checklist S1. Search yield according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses.
doi:10.1371/journal.pone.0114153.s001 (DOC)
Figure 10. Graph demonstrating the PV area comparison of the mean loop for American Heart
Association/American College of Cardiology heart failure stage O (shown in white), the modelled loop
(shown in black) and the intercepting area (shown in grey).
doi:10.1371/journal.pone.0114153.g010
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Diagram S1. Flow diagram for search results according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses.
doi:10.1371/journal.pone.0114153.s002 (DOC)
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